Thermo Fisher Scientific (TMO) Depreciation & Amortization (CF) (2009 - 2026)

Thermo Fisher Scientific has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $306.0 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 10.87% year-over-year to $306.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 5.75% YoY) and the FY2025 annual result came in at $1.0 billion, down 9.17% from the prior year.
• Depreciation & Amortization (CF) improved to $306.0 million in Q1 2026, from $292.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $306.0 million in Q1 2026 and troughed at $227.0 million in Q3 2025.
• A 5-year average of $268.6 million and a median of $270.0 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) gained 26.26% — and 2025, when it declined 21.99%.
• Tracing TMO's Depreciation & Amortization (CF) over 5 years: stood at $256.0 million in 2022, then grew by 7.81% to $276.0 million in 2023, then grew by 10.14% to $304.0 million in 2024, then fell by 3.95% to $292.0 million in 2025, then grew by 4.79% to $306.0 million in 2026.
• Business Quant data shows TMO's Depreciation & Amortization (CF) at $306.0 million in Q1 2026, $292.0 million in Q4 2025, and $227.0 million in Q3 2025.